Business
Kiora Pharmaceuticals Announces Presentation of KIO-101 Clinical Trial Data at the American Society of Cataract and Refractive Surgery 2022
Results support planned Phase 2 Trial to treat the Ocular Presentation of Rheumatoid Arthritis (OPRA) Salt Lake City, Utah--(Newsfile Corp. - April 25, 2022)
About this update from Kiora Pharmaceuticals, Inc.
[{"type":"text","content":"Results support planned Phase 2 Trial to treat the Ocular Presentation of Rheumatoid Arthritis (OPRA)\nSalt Lake City, Utah--(Newsfile Corp. - April 25, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (\"Kiora\" or the \"Company\") announced that the full results of the KIO-101 Phase 1b clinical trial are being presented at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting on April 25, 2022.\nThe results of the vehicle-controlled, randomized clinical trial in patients with ocular surface inflammation demonstrated safety and tolerability of KIO-101 as well as statistically significant improvements in conjunctival hyperemia in the 0.15% KIO-101 arm compared to vehicle control. Conjunctival hyperemia was a key inclusion criterion for the enrollment of patients with ocular surface inflammation and is a recognized clinical sign in patients with ocular surface inflammation and associated dry eye.\n\"One hundred (100%) percent of patients on KIO-101 (compared to 43% vehicle control) showed a reduction of conjunctival hyperemia after 12-days of twice daily topical dosing. This response fell to 36% of patients (compared to 29% vehicle control) 8-days after stopping treatment. This clear drug effect is consistent with the mechanism of action of DHODH inhibition and supports our planned Phase 2 trial later this year for the treatment of dry eye disease in patients with Rheumatoid Arthritis (RA),\" said Eric J Daniels, MD, Chief Development Officer of Kiora. \"This indication, which we refer to as 'Ocular Presentation of RA' (OPRA), has the potential to address a large segment of patients with autoimmune-associated dry eye disease. RA patients, in which systemic DHODH inhibitors are approved, typically have more moderate to severe dry eye symptoms when compared to non-autoimmune dry eye. We believe KIO-101 has the potential to directly address ocular surface T-cell proliferation and ongoing proinflammatory cytokine release, directly targeting an underlying cause of the disease.\"\nPresentation Details:\nPresenter: Gerhard Garhöfer, MD, Associate Professor, Medical University of Vienna and principal investigator of the study.\nTitle: A phase I/2a safety and tolerability study of KIO-101 eye drops in healthy adult volunteers and patients with ocular surface inflammation\nDate & Location: April 25, 2022 during ...